Ladenburg Thalmann Financial Services Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 6.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 493,995 shares of the company’s stock after selling 33,383 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Ladenburg Thalmann Financial Services Inc.’s holdings, making the stock its 24th biggest holding. Ladenburg Thalmann Financial Services Inc.’s holdings in Johnson & Johnson were worth $64,322,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in JNJ. Balentine LLC increased its position in Johnson & Johnson by 33.5% during the 3rd quarter. Balentine LLC now owns 3,394 shares of the company’s stock worth $441,000 after purchasing an additional 851 shares in the last quarter. AlphaStar Capital Management LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth about $642,000. Kalos Management Inc. increased its position in Johnson & Johnson by 16.2% during the 3rd quarter. Kalos Management Inc. now owns 22,181 shares of the company’s stock worth $2,883,000 after purchasing an additional 3,095 shares in the last quarter. Point72 Asset Management L.P. increased its position in Johnson & Johnson by 3.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 689,342 shares of the company’s stock worth $89,621,000 after purchasing an additional 20,278 shares in the last quarter. Finally, Cedar Hill Associates LLC increased its position in Johnson & Johnson by 563.4% during the 3rd quarter. Cedar Hill Associates LLC now owns 13,175 shares of the company’s stock worth $1,713,000 after purchasing an additional 11,189 shares in the last quarter. Institutional investors and hedge funds own 67.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of analysts recently commented on JNJ shares. BTIG Research reiterated a “sell” rating and set a $110.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective for the company. in a research report on Monday, January 8th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets lifted their price target on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $146.26.

In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.19% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) opened at $134.35 on Wednesday. The firm has a market capitalization of $360,450.00, a PE ratio of 24.74, a PEG ratio of 2.19 and a beta of 0.77. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.58 EPS. sell-side analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 61.88%.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Sold by Ladenburg Thalmann Financial Services Inc.” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2018/03/14/johnson-johnson-jnj-shares-sold-by-ladenburg-thalmann-financial-services-inc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.